Biocorrx Stock Price, News & Analysis (OTCMKTS:BICX)

$0.09 0.00 (0.00 %)
(As of 12/14/2017 03:47 PM ET)
Previous Close$0.09
Today's Range$0.09 - $0.09
52-Week Range$0.02 - $0.34
Volume426,554 shs
Average Volume177,640 shs
Market Capitalization$17.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3

About Biocorrx (OTCMKTS:BICX)

BioCorRx, Inc., formerly Fresh Start Private Management, Inc., is a holding company. The Company is an addiction healthcare solutions company operating in Santa Ana, California. The Company, through its subsidiary, Fresh Start Private, Inc., provides alcoholism and opioid treatment program. It offers a medication-assisted treatment program that combines non-addictive medication coupled with psycho-social counseling. It also distributes and licenses the BioCorRx Recovery Program for alcoholism and opioid addiction treatment. The BioCorRxO Recovery Program consists of over two parts, which include an implant, administered by a licensed physician, of a compounded formulation of the drug, Naltrexone (implanted under the skin) (the Implant), which reduces alcohol cravings over a period of time, and a structured, intensive one on one counseling program developed by it. It offers BioCorRx Recovery Program in over 10 locations, including California, Arizona, Atlanta, Illinois and others.

Receive BICX News and Ratings via Email

Sign-up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:BICX
CUSIPN/A
Phone714-462-4880

Debt

Debt-to-Equity Ratio-0.62%
Current Ratio0.27%
Quick Ratio0.27%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$700,000.00
Price / Sales30.51
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-1.76

Profitability

Trailing EPS($0.17)
Net Income$-5,900,000.00
Net Margins-4,897.70%
Return on EquityN/A
Return on Assets-150.00%

Miscellaneous

EmployeesN/A
Outstanding Shares243,240,000

Biocorrx (OTCMKTS:BICX) Frequently Asked Questions

What is Biocorrx's stock symbol?

Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."

How were Biocorrx's earnings last quarter?

Biocorrx Inc. (OTCMKTS:BICX) announced its quarterly earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $0.17 million for the quarter. View Biocorrx's Earnings History.

When will Biocorrx make its next earnings announcement?

Biocorrx is scheduled to release their next quarterly earnings announcement on Thursday, April, 12th 2018. View Earnings Estimates for Biocorrx.

Who are some of Biocorrx's key competitors?

Who are Biocorrx's key executives?

Biocorrx's management team includes the folowing people:

  • Brady J. Granier, President, Chief Executive Officer, Director (Age 43)
  • Lourdes Felix, Chief Financial Officer, Chief Operating Officer, Treasurer, Director (Age 48)
  • Tom Welch, Director - Operations
  • Kent Emry, Director (Age 47)

How do I buy Biocorrx stock?

Shares of Biocorrx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocorrx's stock price today?

One share of Biocorrx stock can currently be purchased for approximately $0.09.

How big of a company is Biocorrx?

Biocorrx has a market capitalization of $17.88 million and generates $700,000.00 in revenue each year. The company earns $-5,900,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How can I contact Biocorrx?

Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]


MarketBeat Community Rating for Biocorrx (BICX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  36
MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biocorrx (OTCMKTS:BICX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Biocorrx (OTCMKTS:BICX) Earnings History and Estimates Chart

Earnings by Quarter for Biocorrx (OTCMKTS:BICX)

Biocorrx (OTCMKTS BICX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/12/2018        
11/17/2016Q3 2016($0.02)$0.17 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biocorrx (OTCMKTS:BICX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Biocorrx (OTCMKTS:BICX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biocorrx (OTCMKTS BICX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.85%
Insider Trades by Quarter for Biocorrx (OTCMKTS:BICX)

Biocorrx (OTCMKTS BICX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/27/2015Jorge Andrade JrDirectorSell125,000$0.06$7,500.00View SEC Filing  
2/26/2015Jorge Andrade JrDirectorSell245,000$0.05$12,250.00View SEC Filing  
2/23/2015Jorge Andrade JrDirectorSell215,000$0.06$12,900.00View SEC Filing  
2/17/2015Jorge Andrade JrDirectorSell90,000$0.08$7,200.00View SEC Filing  
2/10/2015Jorge Andrade JrDirectorSell60,000$0.09$5,400.00View SEC Filing  
10/28/2014Jorge Andrade JrDirectorSell25,000$0.09$2,250.00View SEC Filing  
10/13/2014Jorge Andrade JrDirectorSell80,000$0.09$7,200.00View SEC Filing  
10/7/2014Jorge Andrade JrDirectorSell40,000$0.11$4,400.00View SEC Filing  
10/1/2014Jorge Andrade JrDirectorSell30,000$0.13$3,900.00View SEC Filing  
9/29/2014Jorge Andrade JrDirectorSell170,000$0.10$17,000.00View SEC Filing  
9/22/2014Jorge Andrade JrDirectorSell130,000$0.10$13,000.00View SEC Filing  
9/15/2014Jorge Andrade JrDirectorSell90,000$0.10$9,000.00View SEC Filing  
9/8/2014Jorge Andrade JrDirectorSell95,000$0.11$10,450.00View SEC Filing  
8/22/2014Jorge Andrade JrDirectorSell100,000$0.13$13,000.00View SEC Filing  
8/14/2014Jorge Andrade JrDirectorSell300,000$0.14$42,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biocorrx (OTCMKTS BICX) News Headlines

Source:
DateHeadline
UPDATE: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery ProgramUPDATE: BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery Program
finance.yahoo.com - December 12 at 4:20 PM
BioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx RecoveryBioCorRx Announces Distribution Deal with CereCare, LLC for the BioCorRx Recovery
finance.yahoo.com - December 12 at 11:27 AM
BioCorRxs (BICX) CEO Brady Granier on Q3 2017 Results - Earnings Call TranscriptBioCorRx's (BICX) CEO Brady Granier on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 18 at 1:14 AM
BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone ImplantBioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant
finance.yahoo.com - November 16 at 9:34 AM
BioCorRx Provides Business Update for the Third Quarter of 2017BioCorRx Provides Business Update for the Third Quarter of 2017
finance.yahoo.com - November 16 at 9:34 AM
BioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and VirginiaBioCorRx Announces Nine Centers to Implement BioCorRx Recovery Program Across Maryland and Virginia
finance.yahoo.com - October 25 at 5:56 PM
BioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in PhiladelphiaBioCorRx to Exhibit at the International Association of Chiefs of Police 2017 Annual Conference in Philadelphia
finance.yahoo.com - October 19 at 5:07 PM
BioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol AddictionBioCorRx CEO Brady Granier Appears on MichaeLA on HLN to Discuss Alcohol Addiction
finance.yahoo.com - October 17 at 5:20 PM
BioCorRx To Launch New Weight Management ProgramBioCorRx To Launch New Weight Management Program
finance.yahoo.com - October 5 at 8:04 AM
BioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone Implant - Baystreet.caBioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone Implant - Baystreet.ca
www.baystreet.ca - September 29 at 8:44 AM
BioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone ImplantBioCorRx Inc. Announces Update on Commercialization Efforts for Naltrexone Implant
www.baystreet.ca - September 28 at 10:34 AM
BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use DisorderBioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder
finance.yahoo.com - September 12 at 4:49 PM
BioCorRx to Exhibit at CASAM Conference in San Francisco, CaliforniaBioCorRx to Exhibit at CASAM Conference in San Francisco, California
finance.yahoo.com - August 21 at 4:31 PM
BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017
finance.yahoo.com - August 15 at 5:24 PM
BioCorRx Schedules Second Quarter 2017 Business Update & Earnings Conference CallBioCorRx Schedules Second Quarter 2017 Business Update & Earnings Conference Call
finance.yahoo.com - August 11 at 5:01 PM
Serrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los AngelesSerrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los Angeles
finance.yahoo.com - July 31 at 4:31 PM
BioCorRx Announces EnLite(TM) Clinics to Implement the BioCorRx Recovery Program in Three Clinics in OhioBioCorRx Announces EnLite(TM) Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio
finance.yahoo.com - July 25 at 4:24 PM
BioCorRx Announces First Addiction Treatment Center in South Florida to Implement the BioCorRx ProgramBioCorRx Announces First Addiction Treatment Center in South Florida to Implement the BioCorRx Program
finance.yahoo.com - July 21 at 6:11 PM
BioCorRx to Exhibit at ASAM Conference in Dallas, TexasBioCorRx to Exhibit at ASAM Conference in Dallas, Texas
finance.yahoo.com - July 6 at 4:07 PM
BioCorRx Inc.: BioCorRx to Present at the 2017 Marcum Microcap ConferenceBioCorRx Inc.: BioCorRx to Present at the 2017 Marcum Microcap Conference
www.finanznachrichten.de - June 7 at 4:13 PM
BIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsBIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 8 at 4:04 PM
21st Century Cures Act Hopes To Reduce $41 Billion Annual Cost Of Opioid Treatments21st Century Cures Act Hopes To Reduce $41 Billion Annual Cost Of Opioid Treatments
seekingalpha.com - January 22 at 3:53 PM
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive AgreementBIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - August 3 at 12:30 PM
BIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial StatemenBIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statemen
biz.yahoo.com - May 20 at 5:05 PM
BIOCORRX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and ExhibitsBIOCORRX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - April 18 at 4:13 PM
BIOCORRX INC. Files SEC form 10-K, Annual ReportBIOCORRX INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 14 at 2:55 PM

SEC Filings

Biocorrx (OTCMKTS:BICX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Biocorrx (OTCMKTS BICX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.